To note, in a phase I clinical trial, administration of various amounts of anti-FGF23 antibodies increased tubular maximum transport of phosphate per glomerular filtration rate (TmP/GFR) in adult patients with X-linked hypophosphatemia (XLH) [71, 72]. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.